Establishing plausibility of cardiovascular adverse effects of immunotherapies
Published: 25 May 2023
Establishing plausibility of cardiovascular adverse effects of immunotherapies using Mendelian randomisation
Establishing plausibility of cardiovascular adverse effects of immunotherapies using Mendelian randomisation
Nhu Ngoc Le, Tran Quoc Tran, Clea Du Toit, Dipender Gill, Sandosh Padmanabhan
Summary
Immune checkpoint inhibitors (ICIs) and Janus kinase inhibitors (JAKis) have raised concerns over serious unexpected cardiovascular adverse events. New research by Ngoc Le in the Padmanabhan group leveraged widespread pleiotropy in genome-wide association studies to study the causal effects of 9 cardiovascular risk factors on ischemic stroke risk both independently and by mediation, followed by an interrogation of the implicated expression quantitative trait loci (eQTLs).
The article, published in Frontiers in Cardiovascular Medicine demonstrates the potential to flag adverse effects of drugs early, which informs the design of clinical trials and pharmacovigilance studies.
First published: 25 May 2023